Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 95

Results For "drug"

3160 News Found

Urgent need to redefine pharma companies’ role on several issues of the industry: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
Opinion | July 04, 2024

Urgent need to redefine pharma companies’ role on several issues of the industry: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date


LG Chem enters Chinese osteoarthritis treatment market
News | July 03, 2024

LG Chem enters Chinese osteoarthritis treatment market

Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China


Abbott and YRGCARE inaugurate new outreach centers in India
News | July 02, 2024

Abbott and YRGCARE inaugurate new outreach centers in India

Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases


Briefs: Family Care Hospitals, Laurus Labs and Bafna Pharmaceuticals
News | June 30, 2024

Briefs: Family Care Hospitals, Laurus Labs and Bafna Pharmaceuticals

Laurus Labs receives EIR from USFDA for API facilities


Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India
News | June 29, 2024

Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR


Alembic Pharmaceuticals announces USFDA final approval for Doxycycline Capsules, 40 mg
Drug Approval | June 29, 2024

Alembic Pharmaceuticals announces USFDA final approval for Doxycycline Capsules, 40 mg

Doxycycline capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients


Jubilant Ingrevia receives EIR from USFDA for Unit-1 at Bharuch
Drug Approval | June 28, 2024

Jubilant Ingrevia receives EIR from USFDA for Unit-1 at Bharuch

This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative


Eugia SEZ’s injectable facility gets EIR from USFDA
Drug Approval | June 28, 2024

Eugia SEZ’s injectable facility gets EIR from USFDA

The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated